FDA approves first-in-class non-opioid painkiller 

Jan 31, 2025 - 01:12 PM
FDA-update-generic-drugs

The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to severe acute pain in adults. The drug is manufactured by Vertex Pharmaceuticals. According to the FDA, Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system before pain signals reach the brain. 

Related News Articles

Headline
Hospital-at-home bill considered during House Ways and Means Committee markup
The AHA submitted a statement Sept. 17 for a House Ways and Means Committee markup session on a series of health care and other bills. Specifically, the AHA…
Headline
AHA highlights key health care priorities for House, Senate leaders to address by end of year 
The AHA detailed its key health care priorities for the remainder of the year in comments to House and Senate majority and minority leaders Sept. 15. The AHA…
Headline
FDA issues guidance to expand non-opioid treatments for chronic pain
The Food and Drug Administration Sept. 10 released draft guidance on non-opioid treatments for treating chronic pain and reducing prescription opioid misuse.…
Headline
Study finds less than 40% of Medicare beneficiaries with OUD receive standard care
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
CMS Innovation Center releases FAQ on prior authorization program pilot
The Centers for Medicare & Medicaid Services Innovation Center Aug. 12 released an FAQ on the Wasteful and Inappropriate Service Reduction Model, a six-…
Headline
FDA announces labeling changes to opioid pain medications 
The Food and Drug Administration July 31 announced that it is requiring safety label changes to all opioid pain medications to further emphasize and explain…